HOME >> MEDICINE >> NEWS
First medication to target PCP addiction is reported by Arkansas researchers

Animal studies by researchers at the University of Arkansas for Medical Sciences (UAMS) used an antibody-based drug to provide immediate protection against the chronic abuse of phencyclidine (PCP). The studies mark the first time that a long-acting treatment has been developed to block or reduce the psychoactive effects of PCP in drug addicts, according to UAMS scientist S. Michael Owens, Ph.D. In earlier studies, he used a smaller fragment of the antibody to treat drug overdose.

Owens presented his findings here today at the national meeting of the American Chemical Society, the world's largest scientific society.

Owens said his new technique uses monoclonal antibodies-identical copies of animal antibodies cloned and reproduced in the laboratory-to prevent or slow the entry of PCP into the brain, where it produces its pleasurable effects. The ability to create huge quantities of these antibodies makes it possible to administer a very large dose in a single injection. In the animal studies, just one injection curbed the effects of PCP for at least two weeks-a period equivalent to one to two months in humans, Owens said.

This fast-acting therapy could make a profound difference in the way PCP addicts are treated, enabling doctors to offer addicts an effective anti-addiction medication that works immediately. By contrast, antibody-based approaches to creating vaccines entail weeks of waiting before benefits appear, Owens said.

PCP triggers hallucinations, psychotic behavior, violence, and even self-destruction.

In a 1997 NIDA survey of high school seniors, more than two percent of the students said they had used PCP in the preceding 30 days. "Young people are attracted to PCP even though they know how dangerous it is, because it is inexpensive and because it produces euphoria, hallucinations and a feeling of superhuman strength," said Owens.

The UAMS research is supported by grants from the National Institute for Drug Ab
'"/>

Contact: Charmayne Marsh
y_marsh@acs.org
202-872-4445
American Chemical Society
24-Aug-1999


Page: 1 2

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. First UK cases of previously rare disease reported in gay men
3. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
4. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
5. First US kidney cancer vaccine trial underway at Columbia
6. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
7. First blood test to diagnose paralyzing, blinding disease
8. First US SARS vaccine trial opens at NIH
9. First-ever safety study of medical cannabis use in Canada launched
10. First solid evidence that the study of music promotes intellectual development
11. First medical test on CD gets good results

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/29/2020)... MONTREAL (PRWEB) , ... August 29, 2020 , ... When ... - perhaps with greater ease than most people would. Rather than become melancholic, however, ... yet deep advice on achieving one’s dreams. Randy Pausch took a negative situation and ...
(Date:8/28/2020)... TUCSON, Ariz. (PRWEB) , ... August 28, 2020 ... ... helium-oxygen respiratory assist system designed to help treat patients with respiratory conditions, including ... a mixture of helium and oxygen, but it captures exhaled gas and scrubs ...
(Date:8/28/2020)... ... August 28, 2020 , ... With in-person gluten-free ... to continue helping the specialty-diet community connect with great, gluten-free brands. At the ... enter giveaways, chat with brands & watch over 50 educational classes... all online ...
(Date:8/28/2020)... ... August 28, 2020 , ... Ziegler, a ... on its investment in Synchronous Health, a tech-enabled behavioral health and well-being solutions ... of human empathy with artificial intelligence (AI) to increase access and quality of ...
(Date:8/27/2020)... N.Y. (PRWEB) , ... August 27, 2020 , ... ... DePinto, has joined the Walk-in Dermatology team in its Greenvale, New York location. ... Island Nail and Skin Care Institute. She is certified in chemical peels, microdermabrasion, ...
Breaking Medicine News(10 mins):
(Date:8/27/2020)... ... August 27, 2020 , ... Bleep LLC, maker of the DreamPort mask-less CPAP ... the company’s new spokesperson. , “In my line of work, a good night of ... Bleep DreamPort it was a Bleeping no brainer for me,” said Jensen. “From the ...
(Date:8/26/2020)... ... ... AseptiScope, a privately funded San Diego, California based, clinical innovation company, has been ... , “AseptiScope is pleased to receive this recognition,” said Kelly Powers, AseptiScope cofounder and ... goggles on their eyes, covers on their shoes, and gowns on their bodies will ...
(Date:8/26/2020)... ... 26, 2020 , ... Crossroads Hospice & Palliative Care Chief ... to her name. , That’s thanks to her completion of two additional certifications ... Compliance Officer (CPCO.) , The CHC is designed to mitigate compliance-related risks. ...
Breaking Medicine Technology:
Cached News: